Bromfenac Ophthalmic Solution 0.09% Recalled for Failed Impurities Specifications
Alembic Pharmaceuticals Limited is recalling Bromfenac Ophthalmic Solution 0.09% nationwide due to failed impurities and degradation specifications. Three affected lots expire May 31, 2025.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is a manufacturing quality defect (failed specifications) without confirmed evidence of patient harm.
Plain-English summary
Alembic Pharmaceuticals Limited is recalling Bromfenac Ophthalmic Solution 0.09% (prescription eye drops) distributed nationwide because the product failed to meet impurities and degradation specifications.
The affected lots are: Lot 7230309 (Exp. 5/31/2025), Lot 7230310 (Exp. 5/31/2025), and Lot 7230311 (Exp. 5/31/2025). The product is supplied in 1.7 mL bottles, NDC 62332-508-17, manufactured in India.
Patients currently using this medication should contact their healthcare provider or pharmacist before discontinuing use. Healthcare providers may consider alternative treatments if needed. Do not use recalled product.
The recalled product
- Product
- BROMFENAC OPHTHALMIC SOLUTION 0.09% (BROMFENAC OPHTHALMIC SOLUTION 0.09%)
- Brand
- BROMFENAC OPHTHALMIC SOLUTION 0.09%
- Manufacturer
- Alembic Pharmaceuticals Limited
- Category
- Drug — Ophthalmic / Eye drops
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot 7230309
- Exp Date: 5/31/2025
- Lot 7230310
- Lot 7230311
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BROMFENAC OPHTHALMIC SOLUTION 0.09%
- ModerateCardinal Health Recalls Bromfenac Ophthalmic Solution Due to Storage Temperature Excursions
FDA (Drugs) · 2021-06-02
Same manufacturer · Alembic Pharmaceuticals Limited
See all →- ModerateFesoterodine extended-release tablets recalled over a diester impurity above specification
FDA (Drugs) · 2026-01-14
- ModerateFesoterodine tablets recalled after a diester impurity exceeded its specification limit
FDA (Drugs) · 2025-11-26
- HighDoxepin hydrochloride capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- SevereCelecoxib Capsules 200 mg recalled for foreign tablets inside bottles
FDA (Drugs) · 2025-06-18
- SevereAlembic Pharmaceuticals Recalls Telmisartan Tablets Due to Labeling Error
FDA (Drugs) · 2021-04-14
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08